Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG

NCT02829996 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

201

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Open-Angle Glaucoma (POAG)
Ocular Hypertension (OHT)

Interventions

DRUG: trabodenoson 6.0% / latanoprost 0.005% QD
DRUG: trabodenoson 3.0% / latanoprost 0.005% QD
DRUG: trabodenoson 6.0% / latanoprost 0.0025% QD
DRUG: latanoprost 0.005% QD
DRUG: latanoprost 0.0025% QD

Sponsor

Inotek Pharmaceuticals Corporation